Investment Summary

Alta Partners Invests In Portola Pharmaceuticals

On November 8, 2006, venture capital firm Alta Partners invested in life science company Portola Pharmaceuticals for 46M USD

Investment Highlights
  • This is Alta Partners’ 29th transaction in the Life Science sector.
  • This is Alta Partners’ largest (disclosed) transaction.
  • This is Alta Partners’ 27th transaction in the United States.
  • This is Alta Partners’ 17th transaction in California.
Investment Fate
  • Portola Pharmaceuticals went public in 2013.
  • Portola Pharmaceuticals was sold to a strategic buyer in 2020.

Investment Summary
Date 2006-11-08
Target Portola Pharmaceuticals
Sector Life Science
Investor(s) Alta Partners
Deal Type Venture
Deal Value 46M USD

Target

Portola Pharmaceuticals

South San Francisco, California, United States
Portola Pharmaceuticals, Inc. is a biopharmaceutical company, discovers and develops therapeutics for cardiovascular and autoimmune diseases. Portola Pharmaceuticals was founded in 2003 and is based in South San Francisco, California.

Search 200,197 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Alta Partners

Jackson, Wyoming, United States

Investor Investor Investor Investor

Category Venture Capital Firm
Founded 1996
PE ASSETS 2.6B USD
Size Large
Type Sector Focused
DESCRIPTION

Alta Partners is a venture capital firm that targets investments in early and later stage life science companies, including biopharmaceuticals, medical technology, and information technology businesses. Alta was formed as an early stage investor but has since expanded its investment range to provide later stage growth capital to private and young public companies. Alta was established in 1996 and is headquartered in San Francisco, California.

DEAL STATS #
Overall 33 of 59
Sector (Life Science) 29 of 50
Type (Venture) 27 of 48
State (California) 17 of 31
Country (United States) 27 of 50
Year (2006) 4 of 4
Size (of disclosed) 1 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2006-10-30 Veloxis Pharmaceuticals

Cary, North Carolina, United States

Veloxis Pharmaceuticals is a fully integrated specialty pharmaceutical company that develops a clinically validated drug-delivery platform for overcoming the deficiencies of drugs with low water solubility, thus improving the bioavailability of marketed drugs and new chemical entities (NCEs). Veloxis Pharmaceuticals is based in Cary, North Carolina.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2006-11-27 Innate Pharma

Marseille, France

Innate Pharma is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases. These novel drugs consist of monoclonal antibodies that can activate the innate immune system. Innate Pharma was founded in 1999 and is based in Marseille, France.

Sell -
Mergr

Product

Company

Legal